Favorable effects of ezetimibe alone or in association with simvastatin on the removal from plasma of chylomicrons in coronary heart disease subjects

Imagem de Miniatura
Arquivos
art_MANGILI_Favorable_effects_of_ezetimibe_alone_or_in_association_2014.PDF (708.2 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
MESQUITA, Carlos H.
TANAKA, Akira
SCHAEFER, Ernst J.
Citação
ATHEROSCLEROSIS, v.233, n.1, p.319-325, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Reductions on the clearance from plasma of chylomicrons are associated with atherosclerosis. Statins improve the removal from plasma of chylomicrons in a dose dependent manner. There is controversy whether ezetimibe modifies the plasma clearance of chylomicrons. Effects of ezetimibe alone or in combination with simvastatin were compared with low and high dose of the latter, upon the kinetics of a chylomicron-like emulsion in coronary heart disease (CHD) patients. Methods: 25 CHD patients were randomized for treatment with ezetimibe 10 mg (group 1) or simvastatin 20 mg (group 2) with progression to ezetimibe + simvastatin 10/20 mg or simvastatin 80 mg, respectively. Kinetic studies were performed at baseline and after each treatment period of 6 weeks. The fractional catabolic rates (FCR) of the emulsion labeled with C-14-CE and H-3-TG, that represent respectively chylomicron remnant and triglyceride removal, were calculated. Comparisons were made by ANOVA. Results: The (CE)-C-14-FCR in group 1 were 0.005 +/- 0.004, 0.011 +/- 0.008 and 0.018 +/- 0.005 min(-1) and in group 2 were 0.004 +/- 0.003, 0.011 +/- 0.008 and 0.019 +/- 0.007 min(-1) respectively at baseline, after 6 and 12 weeks (p < 0.05 vs. baseline, and 6 vs. 12 weeks). The H-3-TG-FCR in group 1 were 0.017 +/- 0.011, 0.024 +/- 0.011 and 0.042 +/- 0.013 min(-1) and in group 2 were 0.016 +/- 0.009, 0.022 +/- 0.009 and 0.037 +/- 0.012 min(-1) at baseline, after 6 and 12 weeks (p < 0.05 vs. baseline, and 6 vs. 12 weeks). There were no differences between groups in time. Conclusion: Both treatments increased similarly the removal from plasma of chylomicron and remnants in CHD patients.
Palavras-chave
Simvastatin, Ezetimibe, Chylomicrons, Triglyceride-rich lipoproteins, ApoB-48
URI
https://observatorio.fm.usp.br/handle/OPI/5351
Referências
  1. Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131
  2. [Anonymous], 2009, ANN ICRP, V113, P7
  3. Bishop JR, 2008, CURR OPIN LIPIDOL, V19, P307, DOI 10.1097/MOL.0b013e3282feec2d
  4. Carneiro MM, 2012, ATHEROSCLEROSIS, V221, P268, DOI 10.1016/j.atherosclerosis.2011.12.033
  5. Catapano AL, 2006, CURR MED RES OPIN, V22, P2041, DOI 10.1185/030079906X132721
  6. Cesar TB, 2006, J NUTR, V136, P971
  7. Chan DC, 2002, J LIPID RES, V43, P706
  8. CIANFLONE K, 1990, METABOLISM, V39, P274, DOI 10.1016/0026-0495(90)90047-G
  9. Dallinga-Thie GM, 2010, ATHEROSCLEROSIS, V211, P1, DOI 10.1016/j.atherosclerosis.2009.12.027
  10. Goldberg RB, 2006, MAYO CLIN PROC, V81, P1579
  11. Gouni-Berthold I, 2008, ATHEROSCLEROSIS, V198, P198, DOI 10.1016/j.atherosclerosis.2007.09.034
  12. Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585
  13. GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653
  14. Imagawa M, 2012, CLIN CHIM ACTA, V413, P441, DOI 10.1016/j.cca.2011.10.033
  15. Knopp RH, 2003, INT J CLIN PRACT, V57, P363
  16. Le Ngoc-Anh, 2000, Metabolism Clinical and Experimental, V49, P167, DOI 10.1016/S0026-0495(00)91169-7
  17. Maranhao RC, 1996, ATHEROSCLEROSIS, V126, P15
  18. Marcato LA, 2012, NUKLEONIKA, V57, P607
  19. Marchese SRM, 1998, J RADIOANAL NUCL CH, V232, P233, DOI 10.1007/BF02383745
  20. McGowan MP, 2004, CIRCULATION, V110, P2333, DOI 10.1161/01.CIR.0000145118.55201.15
  21. Nakou ES, 2010, LIPIDS, V45, P445, DOI 10.1007/s11745-010-3409-0
  22. Niemeier A, 1996, J LIPID RES, V37, P1733
  23. Otokozawa S, 2009, ATHEROSCLEROSIS, V205, P197, DOI 10.1016/j.atherosclerosis.2008.11.001
  24. PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336
  25. REDGRAVE TG, 1987, J LIPID RES, V28, P473
  26. REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0
  27. Santos RD, 2000, AM J CARDIOL, V85, P1163, DOI 10.1016/S0002-9149(00)00721-9
  28. Santos RD, 2001, CARDIOVASC RES, V49, P456, DOI 10.1016/S0008-6363(00)00274-1
  29. Schwartz CC, 2004, J LIPID RES, V45, P1594, DOI 10.1194/jlr.M300511.-JLR200
  30. Sposito AC, 2003, ATHEROSCLEROSIS, V166, P311, DOI 10.1016/S0021-9150(02)00334-9
  31. Sposito AC, 2004, ATHEROSCLEROSIS, V176, P397, DOI 10.1016/j.atherosclerosis.2004.05.023
  32. Sposito AC, 2002, ATHEROSCLEROSIS, V161, P447, DOI 10.1016/S0021-9150(01)00661-X
  33. Sposito AC, 2004, J AM COLL CARDIOL, V43, P2225, DOI 10.1016/j.jacc.2003.11.065
  34. Telford DE, 2007, J LIPID RES, V48, P699, DOI 10.1194/jlr.M600139-JLR200
  35. Tremblay AJ, 2006, ARTERIOSCL THROM VAS, V26, P1101, DOI 10.1161/01.ATV.0000216750.09611.ec
  36. Tremblay AJ, 2009, J LIPID RES, V50, P1463, DOI 10.1194/jlr.P800061-JLR200
  37. van Heek M, 2001, BRIT J PHARMACOL, V134, P409, DOI 10.1038/sj.bjp.0704260
  38. VANLENTEN BJ, 1985, J BIOL CHEM, V260, P8783
  39. Weintraub MS, 1996, BRIT MED J, V312, P935
  40. Yunoki K, 2011, ATHEROSCLEROSIS, V217, P486, DOI 10.1016/j.atherosclerosis.2011.04.019

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03